Literature DB >> 18185089

Extensive and partial protein hydrolysate preterm formulas.

Hania Szajewska1.   

Abstract

Protein hydrolysate formulas for preterm infants recently have been developed. However, the indications for the use of such formulas are unclear. The aim of this article is to systematically evaluate the effect of protein hydrolysate formulas in the feeding of preterm infants through searching the MEDLINE (1966-August 2006) and Cochrane Library (Issue 4, 2006) databases. There is little evidence to support the use of extensive and partial protein hydrolysate formulas for preterm infants. High quality, long-term trials are required before these formulas should be offered routinely in preference to other types of formula for preterm infants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18185089     DOI: 10.1097/01.mpg.0000302969.60373.39

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  3 in total

Review 1.  Overview of evidence in prevention and aetiology of food allergy: a review of systematic reviews.

Authors:  Caroline J Lodge; Katrina J Allen; Adrian J Lowe; Shyamali C Dharmage
Journal:  Int J Environ Res Public Health       Date:  2013-11-04       Impact factor: 3.390

2.  Urinary Metabolomic Profile of Preterm Infants Receiving Human Milk with Either Bovine or Donkey Milk-Based Fortifiers.

Authors:  Marzia Giribaldi; Chiara Peila; Alessandra Coscia; Laura Cavallarin; Sara Antoniazzi; Sara Corbu; Giulia Maiocco; Stefano Sottemano; Francesco Cresi; Guido E Moro; Enrico Bertino; Vassilios Fanos; Flaminia Cesare Marincola
Journal:  Nutrients       Date:  2020-07-27       Impact factor: 5.717

3.  Shorter Time to Full Preterm Feeding Using Intact Protein Formula: A Randomized Controlled Trial.

Authors:  Maria Elisabetta Baldassarre; Antonio Di Mauro; Margherita Fanelli; Manuela Capozza; Jennifer L Wampler; Timothy Cooper; Nicola Laforgia
Journal:  Int J Environ Res Public Health       Date:  2019-08-14       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.